Understanding the Mandible Impact and GLP-1: A Comprehensive Guide
In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have become increasingly popular for the treatment of type 2 diabetes and obesity. While these medications have been shown to be effective in improving glycemic control and aiding weight loss, there has been growing concern about their potential impact on dental health, particularly the mandible and oral cavity.
What are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are a class of injectable medications that work by mimicking the action of the natural hormone GLP-1 in the body. The hormone plays a crucial role in regulating blood sugar levels, appetite, and satiety. GLP-1 agonists, such as semaglutide (Ozempic, Wegovy, and Mounjaro), have been shown to improve glycemic control, reduce body weight, and decrease the risk of major adverse cardiovascular events.
The Mandible Impact and GLP-1
Studies have suggested that GLP-1 agonists may have a significant impact on the mandible and oral cavity, leading to a range of dental health complications, including tooth decay, sensitivity, and loss. The symptoms, often referred to as "Ozempic teeth," may be linked to the medication's effect on saliva production and dehydration. Dry mouth, bad breath, and gum disease have also been reported by some individuals taking these medications.
 "Study on GLP-1 Diabetes Medications and Pancreatic Cysts (IPMN)")
